Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims
Among patients with NVAF and OSA, rivaroxaban was associated with a significant reduction in stroke or systemic embolism risk versus warfarin with no difference in major bleeding. Rivaroxaban significantly reduced healthcare resource utilization and costs compared with warfarin, providing support for the use of rivaroxaban in this population.
Authors
- Yuan Zhao (ORCID: https://orcid.org/0000-0002-2826-1873)
- Veronica Ashton (ORCID: https://orcid.org/0000-0003-4880-1897)
- Brahim Bookhart
- Cindy Chen (ORCID: https://orcid.org/0000-0002-5358-7349)
- Alicia K. Campbell (ORCID: https://orcid.org/0000-0001-7070-7835)
- Andrea Natale
- Sanghamitra Mohanty
Institutions
- University of Rome Tor Vergata (IT)
- Johnson & Johnson (United States) (US)
- St David's Medical Center (US)
- Scripps Clinic (US)
- Texas Cardiac Arrhythmia (US)
- Janssen (United States) (US)
- MetroHealth Medical Center (US)
- Janssen Scientific Affairs (United States)
- Case Western Reserve University (US)
Publication Details
- Journal
- Journal of Interventional Cardiac Electrophysiology
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1007/s10840-024-01940-6
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Janssen Scientific Affairs